Androgen receptor-ablative agents
AssigneeThe Ohio State University Research Foundation
InventorsChing-Shih Chen, Dasheng Wang, Jian Yang
Life of this patent
Estimating the term…
Abstract
Compounds of the thiazolidinedione family are provided and shown to be effective androgen receptor ablative agents that can be used in methods of treating or preventing cancer or precancer, including prostate cancer. Also provided are methods of treating or preventing cancer by administering a therapeutically effective amount of one of the androgen receptor ablative agents to a subject in need of such treatment.
Claims20
A compound of Formula I:
- wherein R1 is selected from the group consisting of hydroxyl, amino, halo, hydroxyalkyl, alkylmethoxy, cycloalkylmethoxy, arylmethoxy, NHCOR, NHSO2R, and CH2R;
- wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
- wherein R3 is selected from the group consisting of hydrogen, alkyl, cyclic alkyl, and arylmethoxy;
- and derivatives and metabolites thereof.
A compound of Formula II:
- wherein R is selected from the group consisting of hydrogen, alkyl, allyl, nitrile, ester, carbonyl, amide, and aryl;
- wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
- wherein R3 is selected from the group consisting of hydrogen, allyl, cyclic alkyl, and arylmethoxy;
- and derivatives and metabolites thereof.
A compound of Formula III:
- wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
- and derivatives and metabolites thereof.
A compound of Formula IV:
- wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
- and derivatives and metabolites thereof.
A compound of Formula V:
- wherein R3 is selected from the group consisting of hydrogen, alkyl, cyclic alkyl, and arylmethoxy;
- and derivatives and metabolites thereof.
A compound of Formula VI:
- wherein R3 is selected from the group consisting of hydrogen, alkyl, cyclic allyl, and arylmethoxy;
- and derivatives and metabolites thereof.
A compound of Formula VII:
- wherein R1 is selected from the group consisting of hydroxyl, amino, halo, hydroxyalkyl, alkylmethoxy, cycloalkylmethoxy, arylmethoxy, NHCOR, NHSO2R, and CH2R;
- wherein R2 is selected from the group consisting of hydrogen, bromo, and trifluoromethyl;
- and derivatives and metabolites thereof.
A method of treating, inhibiting, or delaying the onset of a cancer in a subject in need of treatment, the method comprising administering a therapeutically effective amount of a compound of Formula I:
- wherein R1 is selected from the group consisting of hydroxyl, amino, halo, hydroxyalkyl, alkylmethoxy, cycloalkylmethoxy, arylmethoxy, NHCOR, NHSO2R, and CH2R;
- wherein R2 is selected from the group consisting of hydrogen, halo, amino, methoxy, ethoxy, nitro, phenyl, di-alkyl, di-halo, trifluoromethyl, and hydroxyl;
- wherein R3 is selected from the group consisting of hydrogen, allyl, cyclic allyl, and arylmethoxy;
- or a pharmaceutically-acceptable salt thereof, to the subject in need of such treatment.
Dependencies are inferred from the claim text.